Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Jun 28, 2013

NEW YORK (GenomeWeb News) – Jonathan Rothberg has resigned from his position as CEO of Life Technologies' Ion Torrent business, according to a filing with the US Securities and Exchange Commission. Ronnie Andrews, Life Tech's president of genetic and medical sciences, will oversee the Ion Torrent business in addition to continuing in his current role.


Ardy Arianpour is now senior vice president of business development at Ambry Genetics. Previously, he was vice president of business development at the company. Prior to joining Ambry in 2009, he held several positions at Cogenics.


Former Nanosphere President and CEO William Moffitt has taken on the post of executive chairman at GlySure, a company that has developed a glucose monitoring system, the UK-based company said this week.

Moffitt also previously was president and CEO of i-STAT, and he has held executive posts at Baxter Healthcare and American Hospital Supply.


Life BioScience has appointed Lynn L'Archeveque as director of sales and marketing.

In her new role, L'Archeveque will oversee the Albuquerque, NM-based Life Bioscience's line of microarray products and services for the research and clinical diagnostic fields, and will introduce its next-generation, three-dimensional slides to the market, the company said. L'Archeveque has 15 years of experience in biotechnology including former positions with Exelixis, Biocompare, and Schott North America.


The American Clinical Laboratory Association has named Julie Khani to be its senior VP, a new position at the organization. Khani will oversee advocacy and policy operations, and will run a team of three VPs.

She recently was VP of public policy at the National Association of Chain Drug Stores, and before that she was the association's director of federal and legislative affairs. Prior to her 11 years at NACDS, Khani was a legislative manager at Ford Motor Company.


The Wellcome Trust has appointed Kay Davies to be its deputy chairman as of October of this year, when she will take over for Peter Rigby, whose three-year term will be complete. Davies, a professor of anatomy at the University of Oxford, has been a governor of the Wellcome Trust since 2008.

Rigby, former executive chairman of the Institute of Cancer Research, has been reappointed to be a governor for three years, as has Richard Hynes, a professor at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology


Rutgers University said this week that Christopher Molloy will serve as interim chancellor of the new Rutgers Biomedical and Health Sciences program, effective July 1.

Molloy is to hold the post while the university seeks a permanent chancellor for the program, which was created under the New Jersey Medical and Health Sciences Education Restructuring Act.

The act will put several programs under the new one, including most of the schools and institutes that make up the University of Medicine and Dentistry of New Jersey; the Ernest Mario School of Pharmacy; the Rutgers College of Nursing; and the Institute for Health, Health Care Policy, and Aging Research.

Molloy has been managing the integration process so far. He is a molecular and cellular pharmacologist who has been interim provost for biomedical and health sciences at Rutgers since 2011.


Multiplicom said this week that it has appointed Ian Gilham as chairman of the board.
Gilham was first COO, then CEO of in vitro diagnostics company Axis-Shield until it was acquired by Alere in November 2011. Prior to this, he was vice president of pharmacogenetics at GlaxoSmithKline. He has also held general management, marketing, business development, and R&D positions at Abbott Laboratories, Celltech, and Amersham.


Combimatrix's shareholders have re-elected their board of directors to continue serving until the 2014 shareholder meeting. The re-elected board includes Mark McDonough, Judd Jessup, Richard Hockett, Scott Gottlieb, Wei Richard Ding, and Jeremy Jones.


Texas Biomed has appointed Michael Olivier to be a scientist in the Department of Genetics at the Texas Biomedical Research Institute. Olivier currently is director of the Wisconsin Center of Excellence in Genomics Science at the Medical College of Wisconsin.

Olivier's research is focused on metabolic syndrome in humans. He is using family-based genome-wide analysis and candidate gene studies to understand the genetic alterations that affect lipid metabolism, plasma lipid levels, and disease manifestations of these abnormalities.


Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.